A Brain Imaging Study of Nicotine Release in Cigarette Smokers

This study has been terminated.
(It was decided to use a different protocol with a different radioligand)
Sponsor:
Collaborator:
Herzog Hospital
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00254358
First received: November 15, 2005
Last updated: July 3, 2008
Last verified: June 2008
  Purpose

Tobacco Smoking is the most prevalent addiction in society today causing directly major health hazards and sharing morbidity with other psychiatric disorders. Nicotine binds to acetylcholine receptors and thus elevates DA release and inhibits DA transport. There are few studies using advanced brain imaging techniques to investigate how nicotine releases dopamine in humans. These studies utilized dopamine displacement paradigms with [11C] Raclopride binding to D2 receptor in Positron Emission Tomography (PET). There is evidence that smokers (particularly those who enjoyed smoking) showed decreased [11C] Raclopride binding in the caudate/nucleus accumbens and putamen after smoking cigarettes. These results also indicated that the effects of nicotine on dopaminergic neurotransmission are mediated by pleasure and craving. We propose to investigate the effects of smoking a cigarette ad lib on dopamine release by using dopamine competition paradigm with [I123] IBZM in SPECT. Secondly, we will test the hypothesis that dopamine deficiency is a major vulnerability factor for smoking. This may provide further evidence that dopamine deficiency in some smokers pre-disposes them to enjoy and desire smoking cigarettes more than others.


Condition
Nicotine Dependence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Brain Imaging Study of Nicotine Release in Cigarette Smokers

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Enrollment: 0
Study Start Date: April 2007
Study Completion Date: April 2007
  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

smokers in treatment with bupropion

Criteria

Inclusion Criteria:

  • Chronic smokers and healthy non-smokers.

Exclusion Criteria:

  • Pregnant and breast feeding women.
  • Age below 20.
  • Neurological disorders.
  • Others drugs.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00254358

Sponsors and Collaborators
Hadassah Medical Organization
Herzog Hospital
Investigators
Principal Investigator: Yodphat Krausz, MD Hadassah Medical Organization
  More Information

No publications provided

Responsible Party: Dr. Aviv Weinstein, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00254358     History of Changes
Other Study ID Numbers: 842902-HMO-CTIL
Study First Received: November 15, 2005
Last Updated: July 3, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
Nicotine
Dopamine
IBZM

Additional relevant MeSH terms:
Tobacco Use Disorder
Substance-Related Disorders
Mental Disorders
Nicotine
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014